Does Cell Type in Lung Cancer Have any Clinical  Importance?

Cabir  Yüksel

doi:10.5152/EurJTher.2018.1002

Authors

Cabir Yüksel Department of Thoracic Surgery, Ankara University School of Medicine, İbni Sina Hospital, Ankara, Turkey

DOI:

https://doi.org/10.5152/EurJTher.2018.1002

Keywords:

Lung cancer, cell type, cancer

Abstract

Lung cancer is the leading cause of deaths from cancer in men (20%), and it has reached 16.5% and started to surpass deaths due to breast cancer in women. Lung tumors include many subtypes according to the classification of the World Health Organization. These tumors are primarily classified as small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) from the aspects of disease presentation, potential of metastasis, clinical presentation, response to treatment and survival time. NSCLC constitutes nearly 80-85% of all lung cancers. NSCLCs are classified in different subtypes. The two predominant NSCLC histological subtypes are adenocarcinoma and squamous cell carcinoma. Adenocarcinomas have become the most commonly seen subtype of lung cancers (40%). The incidence of Squamous cell carcinoma has decreased in the last few decades and it is estimated to constitute 20-30% of all lung cancers today. Subtypes of NSCLC develop due to different factors, exhibit different clinical and radiological presentations, and consequently respond differently to surgical treatment and chemotherapeutic agents.

Metrics

Metrics Loading ...

References

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 2015; 10: 1243-60.

Mooi WJ, Dingemans KP, Wagenaar SS, Hart AAM, Wagenvoort CA. Ultrastructural heterogeneity of lung carcinomas: Representativity of samples for electron microscopy in tumor classification. Hum Pathol 1990; 21: 1227 34.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-80.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.

Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006; 24: 1700-4.

Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345-61.

Horn L, Pao W. EML4-ALK: honing in on a new target in non-smallcell lung cancer. J Clin Oncol 2009; 27: 4232-5.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non- small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.

Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010; 29: 49- 60.

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010; 28: 4769-77.

Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011; 223: 219-29.

Nicolson MC, Fennell DA, Ferry D, O’Byrne K, Shah R, Potter V, et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 2013; 8: 930-9.

Itoh S, Ikeda M, Isomura T, Endo T, Yamakawa K, Itoh K, et al. Screening helical CT for mass screening of lung cancer: Application of lowdose and single-breath-hold scanning. Radiat Med 1998; 16: 75-83.

Mori M, Chiba R, Takahashi T. Atypical adenomatous hyperplasia of the lung and its differentiation from adenocarcinoma. Characterization of atypical cells by morphometry and multivariate cluster analysis. Cancer 1993; 72: 2331-40.

Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol 2006; 1: 331-48.

Davies SJ, Gosney JR, Hansell DM, Wells AU, du Bois RM, Burke MM, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 2007; 62: 248-52.

Tomashefski J, Connors AF, Rosenthal ES, Hsiue IL. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med 1990; 114: 468-74.

Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75: 191- 202.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/ american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.

Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24: 653-64.

Travis WD. Pathology of lung cancer. Clin Chest Med 2011; 32: 669- 92.

Hirsch FR, Matthews MJ, Aisner S, Campobasso O, Elema JD, Gazdar AF, et al. Histopathologic classification of small cell lung cancer, Changing concepts and terminology. Cancer 1988; 62: 973-7.

Kreisman H, Wolkove N, Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule. Chest 1992; 101: 225-31.

Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clasification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22: 934-44.

Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001; 91: 1992-2000.

Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H. Large cell neuro-endocrine carcinoma of the lung: A histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998; 22: 526-37.

Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ, et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989; 7: 1614-20.

Schleusener JT, Tazelaar HD, Jung SH, Cha SS, Cera PJ, Myers JL, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 1996; 77: 1284-91.

Pass HI, Doppman JL, Nieman L, Stovroff M, Vetto J, Norton JA, et al. Management of the ectopic ACTH syndrome due to thoracic carcinoids. Ann Thorac Surg 1990; 50: 52-7.

Stamatis G, Freitag L, Greschuchna D. Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases. Eur J Cardiothorac Surg 1990; 4: 527-32.

Fishback NF, Travis WD, Moran CA, Guinee DG Jr, McCarthy WF, Koss MN. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 1994; 73: 2936-45.

Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009; 33: 1752-64.

Inamura K, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Fukayama M, et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol 2005; 29: 660-5.

Geurts TW, Nederlof PM, van den Brekel MW, van’t Veer LJ, de Jong D, Hart AA, et al. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res 2005; 11: 6608-14.